Value through Innovation23 April 2014
  • Home
  • Research & Development

Our Research & Development Drive

Research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of innovative, new medicines for the treatment of diseases with an unmet therapeutic need. Furthermore, in our constant quest for pharmaceutical innovation we have successful ongoing collaborations and are actively seeking new collaborations with external partners, ranging from academic institutions to biopharmaceutical enterprises and start-up companies.

Research & Development in detail

  • Research Areas

    Our drug research focuses on the following main areas: respiratory diseases, cardiometabolic diseases, oncology, diseases of the central nervous system and immunology.

  • Research Centres

    Boehringer Ingelheim conducts research and development of drugs in five locations. Germany is the largest research and development facility in the business association of Boehringer Ingelheim.

  • Drug Discovery

    From the first study of a drug to a marketable drug is a long and challenging journey. It takes an average of twelve years from the beginning of the research to the approved drug.

  • Awards & Fellowships  

    Promoting basic research is a prerequisite to Boehringer Ingelheim's research & development mission and an integral part of our social responsibility.

  • Scientific Publications

    Overview of all publications of the last three years (YTD) where employees of Boehringer Ingelheim worldwide were involved.

     

Boehringer Ingelheim's Research & Development facts:

Research and development activities, with our large research sites in Germany (Biberach), the USA (Ridgefield) and Austria (Vienna), were focused on various therapeutic areas such as:

  • Respiratory diseases
  • Cardiovascular diseases
  • Metabolism
  • Oncology
  • Diseases of the central nervous system
  • Immunology

During the past decade, from 2004 to 2013, Boehringer Ingelheim conducted or sponsored 1,377 studies with approximately one million patients on 119 substances in 98 countries.

More than 7,700 highly qualified people of Boehringer Ingelheim’s over 47,400 employees worldwide work in Research & Development.

In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure in Prescription Medicines corresponds to 22.4% of the net sales generated in this business.

Oncology Websites

No flash player detected. For optimized usage of this website your browser should support shockwave flash. For downloading see Macromedia Flash Player

Research & Development

Research & Development